Posttransplant lymphoproliferative disorder in pancreas transplantation: A single-center experience

Transplantation

Volumn 80, Issue 5, 2005, Pages 613-622

  Paraskevas, Steven ^a   Coad, James E ^b   Gruessner, Angelika ^a   Kandaswamy, Raja ^a   Humar, Abhinav ^a   Sutherland, David E R ^a   Gruessner, Rainer W G ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE   (United States)

Author keywords

Cytomegalovirus; Lymphoma; Outcomes; Pancreas

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BONE MARROW CELL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; RISK ASSESSMENT; VIRUS INFECTION;

ADULT; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 25444503010     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000168366.07896.d7     Document Type: Article

References (38)

1. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41(11Pt 1):4262.
2. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133(1): 173.
3. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989; 135(6): 977.
4. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14(1): 8.
5. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68(10): 1517.
6. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20(5): 1346.
7. Kroes AC, van der Fiji, JW, van Tol, MJ, et al. Rapid occurrence of lymphoproliferative disease after pancreas-kidney transplantation performed during acute primary Epstein-Barr virus infection. Clinical Infectious Diseases 1997; 24(3): 339.
8. Martinenghi S, Dell'Antonio G, Secchi A, et al. Cancer arising after pancreas and/or kidney transplantation in a series of 99 diabetic patients. Diabetes Care 1997; 20(3): 272.
9. Keay S, Oldach D, Wiland A, et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998; 26(3): 596.
10. Drachenberg CB, Abruzzo LV, Klassen DK, et al. Epstein-Barr virus-related posttransplantation lymphoproliferative disorder involving pancreas allografts: histological differential diagnosis from acute allograft rejection. Hum Pathol 1998; 29(6): 569.
11. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66(12): 1770.
12. Davis CL Interferon and cytotoxic chemotherapy for the treatment of posttransplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3(2): 108.
13. O'Dwyer, ME, Launder T, Rabkin JM, Nichols CR. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab. Leuk Lymphoma 2000; 39(3-4): 411.
14. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1):113.
15. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and longterm follow-up of 42 adult patients. Transplantation 2001;71(8):1076.
16. Egidi MF, Trofe J, Stratta RJ, et al. Posttransplant lymphoproliferative disorders: Single center experience. Transplant Proc 2001;33(1-2): 1838.
17. Isaacson PG. The revised European-American lymphoma (REAL) classification. Clin Oncol (R Coll Radiol) 1995; 7(6): 347.
18. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4(1): 87.
19. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14(2): 214.
20. Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol. 2002;103(3 Pt 1):249.
21. Varela-Calvino R, Ellis R, Sgarbi G, et al. Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes. Diabetes 2002; 51(6): 1745.
22. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2001; 19(1): 8.
23. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003; 46(3): 305.
24. Nonaka K, Toyoshima H, Namba M, Tarui S. Various phenotypes of diabetes mellitus at ultimate outcome of acutely developed diabetic state induced by viral infection. Endocrinol Jpn 1982; 29(1): 87.
25. Sairenji T, Daibata M, Sorli CH, et al. Relating homology between the Epstein-Barr virus BOLF1 molecule and HLA-DQwS beta chain to recent onset type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34(1): 33.
26. Bouter KP, Meyling FH, Hoekstra JB, et al. Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res 1992; 19(2): 77.
27. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of posttransplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88(10): 1330.
28. Manez R, Breinig MK, Linden P, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994;7:S235.
29. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176(6): 1462.
30. Holmes RD, Orban-Eller K, Karrer FR, et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74(3): 367.
31. Boldogh I, Huang ES, Rady P, et al. Alteration in the coding potential and expression of H-ras in human cytomegalovirus-transformed cells. Intervirology 1994; 37(6): 321.
32. Cinatl J Jr, Cinatl, J, Vogel JU, et al. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 1996; 39(4): 259.
33. Hornef MW, Bein G, Fricke L, et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995; 60(5): 474.
34. Aalto SM, Linnavuori K, Peltola H, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998; 56(3): 186.
35. Graczyk MJ, Paraskevas S, Gruessner RWG, Coad JE. Post-transplant lymphoma after abdominal organ transplantation: An association with cytomegalovirus. Am J Transplant 2001;1:402.
36. Manila PS, Aalto SM, Heikkila L, et al. Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001; 15(5): 337.
37. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96(13): 4055.
38. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, et al. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000; 65(2): 171.